Skip to content
OpenCapital
Get started

CorMedix CRMD Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$127.4MBeat by $22.4MDiluted EPS$0.43Beat by $0.08
Revenue estimate$105.0M
EPS estimate$0.35

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$96.0M
EPS estimate$0.26

Financials

Q1 2026

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$680.18M+33.7%
P/E3.8×—
P/S1.7×-4.5×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Current ratio3×-1.2×

Segments

By product

See full
DefenCath$97.5M+150%
Melinta Portfolio$24.4M—
Contract revenue$5.5M—

Versus estimates

Revenue

Q1 2026$127.4MBeat by $22.4M
Q4 2025$128.6MBeat by $1.6MQ3 2025$104.3MMiss by $22.7MQ2 2025$39.7MMiss by $2.7MQ1 2025$39.1MBeat by $9.2MQ4 2024$31.2MMiss by $58.1K

Diluted EPS

Q1 2026$0.43Beat by $0.08
Q4 2025$0.61Miss by $0.25Q3 2025$0.57Beat by $0.09Q2 2025$0.28Beat by $0.08Q1 2025$0.30Beat by $0.05Q4 2024$0.22Beat by $0.05

Ask the moment CorMedix reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did CorMedix report Q1 2026 earnings?
CorMedix (CRMD) reported Q1 2026 earnings on May 14, 2026 before market open.
What were CorMedix's Q1 2026 revenue and EPS?
CorMedix reported revenue of $127.4M and diluted EPS of $0.43 for Q1 2026.
Did CorMedix beat estimates in Q1 2026?
Revenue beat the consensus estimate of $105.0M by $22.4M. EPS beat the consensus estimate of $0.35 by $0.08.
How did CorMedix's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 226.0% from $39.1M a year earlier and diluted EPS grew 43.3% from $0.30.
Where can I find CorMedix's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001410098-26-000020) and the 10-Q periodic report (0001410098-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.